{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06393738",
            "orgStudyIdInfo": {
                "id": "ARV-393-101"
            },
            "organization": {
                "fullName": "Arvinas Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.",
            "officialTitle": "A Phase 1 First in Human Study of ARV-393 in Adult Participants With Advanced Non-Hodgkin's Lymphoma",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-of-arv-in-relapsed-refractory-non-hodgkin-lymphoma"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04-30",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-04-25",
            "studyFirstSubmitQcDate": "2024-04-30",
            "studyFirstPostDateStruct": {
                "date": "2024-05-01",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-30",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-01",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Arvinas Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a possible treatment option.\n\nARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas, which may prevent, slow or stop tumor growth. This is the first time ARV-393 will be used by people. The investigational drug will be given as an oral tablet.",
            "detailedDescription": "This is an open-label, multicenter, phase 1, dose escalation study to evaluate the safety, tolerability and preliminary anti-tumor activity of ARV-393 as a single agent in adult patients with relapsed/refractory non-Hodgkin lymphoma."
        },
        "conditionsModule": {
            "conditions": [
                "Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)",
                "Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)"
            ],
            "keywords": [
                "Relapsed/Refractory B cell Non Hodgkin Lymphoma (NHL)",
                "Relapsed/Refractory Angioimmunoblastic T-cell lymphoma (AITL)",
                "Advanced non-Hodgkin Lymphoma",
                "advanced NHL",
                "relapsed non-Hodgkin Lymphoma",
                "refractory non-Hodgkin Lymphoma",
                "B Cell Advanced Non-Hodgkin Lymphoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "The study will be initiated with the starting dose. The dose may be escalated to higher dose cohorts or de-escalated to lower dose cohorts based upon the safety and tolerability and as per a Cohort Review Committee recommendation. Backfill cohorts may be initiated at a previously cleared dose with select NHL subtypes",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 112,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Dose escalation",
                    "type": "EXPERIMENTAL",
                    "description": "Dose escalation will begin at Dose Level 1. Dose escalation or de-escalation decision will be recommended by the cohort review committee.",
                    "interventionNames": [
                        "Drug: ARV-393"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "ARV-393",
                    "description": "Oral dose of ARV-393 at a specified dose schedule will be taken in 28-day cycles",
                    "armGroupLabels": [
                        "Dose escalation"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of Dose limiting toxicities during Cycle 1 (28 days)",
                    "description": "Percentage of participants in dose escalation arm at a given dose cohort with AEs meeting protocol defined dose limiting toxicities during cycle 1 (28 days)",
                    "timeFrame": "28 days from first study dosing"
                },
                {
                    "measure": "Percentage of participants with Adverse Events characterized by severity, seriousness, and relationship to study drug as a measure of safety and tolerability",
                    "description": "Adverse events as characterized by type, frequency, severity, seriousness, and relationship to study drug",
                    "timeFrame": "From the study baseline to at least 30 days after last dose of ARV-393"
                },
                {
                    "measure": "Number of participants with abnormal vital signs, abnormal ECG readings ( QT interval) and abnormal laboratory parameters.",
                    "description": "Shifts in vital signs, ECGs, and laboratory parameters from study baseline",
                    "timeFrame": "From the study baseline to at least 30 days after last dose of ARV-393"
                },
                {
                    "measure": "Percentage of participants with Grade 3 or Grade 4 clinical lab abnormalities using the Common Terminology Criteria for Adverse Events (CTCAE) with scale from Grade 1 Grade 5. Higher score means worse outcome.",
                    "description": "Incidence of Grade 3 and Grade 4 clinical laboratory abnormalities",
                    "timeFrame": "From the study baseline to at least 30 days after last dose of ARV-393"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Area under the plasma concentration-time curve (AUC) for ARV-393",
                    "description": "Assessment of pharmacokinetic parameter AUC",
                    "timeFrame": "4 months from first drug dosing"
                },
                {
                    "measure": "Maximum concentration (Cmax) for ARV-393",
                    "description": "Cmax is an assessment of pharmacokinetic parameter",
                    "timeFrame": "4 months from first drug dosing"
                },
                {
                    "measure": "Minimum concentration (Cmin) for ARV-393",
                    "description": "Cmin is an assessment of pharmacokinetic parameter",
                    "timeFrame": "4 months from first drug dosing"
                },
                {
                    "measure": "Time to maximum concentration (Tmax) for ARV-393",
                    "description": "Tmax is an assessment of pharmacokinetic parameter",
                    "timeFrame": "4 months from first drug dosing"
                },
                {
                    "measure": "Oral clearance (CL/F) for ARV-393",
                    "description": "CL/F is an assessment of pharmacokinetic parameter",
                    "timeFrame": "4 months from first drug dosing"
                },
                {
                    "measure": "Volume of distribution (Vd/F) for ARV-393",
                    "description": "Vd/F is a proportionality factor that relates the amount of drug in the body to the concentration of drug measured in a biological fluid.",
                    "timeFrame": "4 months from first drug dosing"
                },
                {
                    "measure": "Overall response rate (ORR) in participants",
                    "description": "ORR is a parameter measuring the anti-tumor activity of ARV-393. it is the percentage of participants reaching a complete response or partial response to the study treatment according to the Lugano response criteria for Non-Hodgkin Lymphoma.",
                    "timeFrame": "Approximately 2 years"
                },
                {
                    "measure": "Complete response rate (CRR)",
                    "description": "CRR is a parameter measuring the anti-tumor activity of ARV-393. CRR is percentage of participants with best of response reported as complete response according to the Lugano response criteria for Non-Hodgkin Lymphoma",
                    "timeFrame": "Approximately 2 years"
                },
                {
                    "measure": "Duration of response (DOR)",
                    "description": "DOR is the time from the initial response (CR or PR) to the date of progression, or death, whichever occurs first. It is a parameter measuring the anti-tumor activity of ARV-393",
                    "timeFrame": "Approximately 2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Eligible participants aged \u226518 years.\n* Have relapsed/refractory mature B-cell non-Hodgkin lymphoma (NHL) and \u22652 prior systemic therapies, or histologically confirmed AITL that has recurred or progressed following institutional standard-of-care therapy.\n* Participants must also have \u22651 measurable lesion at study entry\n* Eastern Cooperative Oncology Group performance status of 0 or 1,\n* Freshly biopsied or archival tumor tissue available,\n* Participants with adequate organ function,\n* Participants must accept and follow pregnancy prevention guidance.\n\nExclusion Criteria:\n\n* No prior allogeneic stem cell transplant or solid organ transplantation, Autologous stem cell transplant, must not have occurred \u2264100 days, previous CAR T-cell therapy \u226460 days, radiotherapy \u2264 2 weeks, systemic anticancer treatment \u2264 5 half-lives or 4 weeks, prior to ARV-393 treatment initiation.\n* Participants must not have significant acute or chronic medical illness, including hypereosinophilic syndrome, active interstitial lung disease or pneumonitis, active or uncontrolled infection, or the presence of laboratory abnormalities, that places participants at unacceptable risk if participating in this study.\n* Participants with an inability to comply with listed prohibited treatments.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Arvinas Androgen Receptor, Inc.",
                    "role": "CONTACT",
                    "phone": "475-345-0791",
                    "email": "clinicaltrialsARV-393@arvinas.com"
                }
            ],
            "locations": [
                {
                    "facility": "Clinical Trial Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48201",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "New Brunswick",
                    "state": "New Jersey",
                    "zip": "10065",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.48622,
                        "lon": -74.45182
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10016",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Westbury",
                    "state": "New York",
                    "zip": "11590",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.75566,
                        "lon": -73.58763
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44122",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Pamplona",
                    "zip": "31008",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 42.81687,
                        "lon": -1.64323
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008223",
                    "term": "Lymphoma"
                },
                {
                    "id": "D000008228",
                    "term": "Lymphoma, Non-Hodgkin"
                },
                {
                    "id": "D000016399",
                    "term": "Lymphoma, T-Cell"
                },
                {
                    "id": "D000016411",
                    "term": "Lymphoma, T-Cell, Peripheral"
                },
                {
                    "id": "D000016393",
                    "term": "Lymphoma, B-Cell"
                },
                {
                    "id": "D000007119",
                    "term": "Immunoblastic Lymphadenopathy"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                },
                {
                    "id": "D000072281",
                    "term": "Lymphadenopathy"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18828",
                    "name": "Lymphoma, B-Cell",
                    "asFound": "B-Cell Non-Hodgkin Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18829",
                    "name": "Lymphoma, T-Cell",
                    "asFound": "T-cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18833",
                    "name": "Lymphoma, T-Cell, Peripheral",
                    "asFound": "T-cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10167",
                    "name": "Immunoblastic Lymphadenopathy",
                    "asFound": "Angioimmunoblastic T-cell lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11222",
                    "name": "Lymphoma, Non-Hodgkin",
                    "asFound": "Non-Hodgkin Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M994",
                    "name": "Lymphadenopathy",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T640",
                    "name": "B-cell Lymphoma",
                    "asFound": "B-Cell Non-Hodgkin Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4496",
                    "name": "Peripheral T-cell Lymphoma",
                    "asFound": "T-cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T391",
                    "name": "Angioimmunoblastic T-cell Lymphoma",
                    "asFound": "Angioimmunoblastic T-cell lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T390",
                    "name": "Angioimmunoblastic Lymphadenopathy With Dysproteinemia",
                    "asFound": "Angioimmunoblastic T-cell lymphoma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}